NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

1. NVCR presented Phase 3 PANOVA-3 trial data for pancreatic cancer. 2. TTFields therapy showed 2.0-month median overall survival improvement. 3. One-year survival rate rose to 68.1% with TTFields therapy. 4. Pain-free survival extended by 6.1 months using TTFields therapy. 5. NVCR stock price fell 8.63% following data release.